ProfileGDS5678 / 1437986_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 52% 54% 49% 53% 55% 52% 55% 54% 55% 53% 54% 54% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3911954
GSM967853U87-EV human glioblastoma xenograft - Control 23.2687852
GSM967854U87-EV human glioblastoma xenograft - Control 33.3224554
GSM967855U87-EV human glioblastoma xenograft - Control 43.1180549
GSM967856U87-EV human glioblastoma xenograft - Control 53.2569953
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4537155
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3461252
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.373955
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3017754
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3421455
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3044953
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3048154
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.339954
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3068653